Pulmonary involvement in primary systemic vasculitides.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
24 12 2021
Historique:
pubmed: 1 4 2021
medline: 22 2 2022
entrez: 31 3 2021
Statut: ppublish

Résumé

This study describes the spectrum and initial impact of pulmonary manifestations in the primary systemic vasculitides. Description and comparison of pulmonary manifestations in adults with Takayasu's arteritis (TAK), GCA, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic GPA (EGPA), polyarteritis nodosa (PAN) and IgA vasculitis (IgAV), using data collected within the Diagnostic and Classification Criteria in Vasculitis study. Data from 1952 patients with primary vasculitides were included: 170 TAK, 657 GCA, 555 GPA, 223 MPA, 146 EGPA, 153 IgAV and 48 PAN. Pulmonary manifestations were observed in patients with TAK (21.8%), GCA (15.8%), GPA (64.5%), MPA (65.9%), EGPA (89.0%), PAN (27.1%) and IgAV (5.9%). Dyspnoea occurred in patients with TAK (14.7%), GCA (7.8%), GPA (41.8%), MPA (43.5%), EGPA (65.8%), PAN (18.8%) and IgAV (2.6%). Cough was reported in TAK (7.6%), GCA (9.3%), GPA (34.8%), MPA (37.7%), EGPA (55.5%), PAN (16.7%) and IgAV (3.3%). Haemoptysis occurred mainly in patients with ANCA-associated vasculitis (AAV). Fibrosis on imaging at diagnosis was documented in GPA (1.9%), MPA (24.9%) and EGPA (6.3%). Only patients with AAV (GPA 2.7%, MPA 2.7% and EGPA 3.4%) required mechanical ventilation. At 6 months, the presence of at least one pulmonary item in the Vasculitis Damage Index was observed in TAK (4.1%), GCA (3.3%), GPA (15.4%), MPA (28.7%), EGPA (52.7%), PAN (6.2%) and IgAV (1.3%). Pulmonary manifestations can occur in all primary systemic vasculitides, but are more frequent and more often associated with permanent damage in AAV.

Identifiants

pubmed: 33788906
pii: 6206791
doi: 10.1093/rheumatology/keab325
pmc: PMC8857773
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

319-330

Subventions

Organisme : Medical Research Council
ID : MR/N011775/1
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

Respir Med. 2018 Dec;145:182-191
pubmed: 30509707
QJM. 2018 Oct 1;111(10):747-748
pubmed: 29727007
Ann Intensive Care. 2017 Dec;7(1):39
pubmed: 28382598
Chest. 2002 Oct;122(4):1497-8
pubmed: 12377894
Semin Arthritis Rheum. 2013 Feb;42(4):391-400
pubmed: 22985708
Arthritis Res Ther. 2020 Jun 5;22(1):131
pubmed: 32503678
Am J Respir Crit Care Med. 1996 Jan;153(1):450-3
pubmed: 8542157
Mayo Clin Proc. 2004 Sep;79(9):1151-7
pubmed: 15357037
Breathe (Sheff). 2018 Sep;14(3):e105-e110
pubmed: 30364520
Q J Med. 1970 Oct;39(156):461-84
pubmed: 5532953
Medicine (Baltimore). 2014 Nov;93(24):340-349
pubmed: 25500703
Arthritis Rheum. 1996 Oct;39(10):1754-60
pubmed: 8843868
BMC Pulm Med. 2014 Jan 28;14:8
pubmed: 24468083
Eur Respir J. 1994 Dec;7(12):2252-4
pubmed: 7713213
Clin Exp Nephrol. 2013 Oct;17(5):619-621
pubmed: 23996327
Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S48-59
pubmed: 16859597
Clin Med Insights Circ Respir Pulm Med. 2015 Sep 23;9(Suppl 1):51-6
pubmed: 26448696
J Rheumatol. 2014 Dec;41(12):2439-46
pubmed: 25274886
Chest. 2006 Feb;129(2):452-465
pubmed: 16478866
Hum Pathol. 1993 Jul;24(7):717-24
pubmed: 8100552
Rheum Dis Clin North Am. 2015 May;41(2):315-31
pubmed: 25836645
Chest. 2001 May;119(5):1608-10
pubmed: 11348978
BMC Immunol. 2014 May 27;15:20
pubmed: 24884372
Intern Med. 2018 Jan 1;57(1):81-84
pubmed: 29033424
Ann Intern Med. 1984 Nov;101(5):594-7
pubmed: 6486590
Rheumatology (Oxford). 2011 Nov;50(11):2035-43
pubmed: 21873269
Rheumatol Adv Pract. 2018 Aug 16;2(2):rky026
pubmed: 31431972
Eur Respir J. 2016 Nov;48(5):1429-1441
pubmed: 27587545

Auteurs

Jean-Paul Makhzoum (JP)

Vasculitis Clinic, Department of Medicine, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, QC, Canada.

Peter C Grayson (PC)

Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD, USA.

Cristina Ponte (C)

Hospital de Santa Maria, Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Faculdade de Medicina, Lisbon, Portugal.

Joanna Robson (J)

Academic Rheumatology Unit, Bristol Royal Infirmary, Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK.
School of Clinical Sciences, University of Bristol and Department of Rheumatology, University Hospitals Bristol NHS Trust, Bristol, UK.

Ravi Suppiah (R)

Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand.

Richard A Watts (RA)

Oxford NIHR Biomedical Research Centre, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Department of Medicine, Norwich Medical School, University of East Anglia, Norwich, UK.

Raashid Luqmani (R)

Oxford NIHR Biomedical Research Centre, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Peter A Merkel (PA)

Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA.

Christian Pagnoux (C)

Vasculitis Clinic, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH